Xenon Pharmaceuticals (XENE) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

—

Revenue (quarter)

—

Revenue growth (year over year)

—

Gross profit (trailing twelve months)

—

Gross margin

—

Net income (trailing twelve months)

—

Net income (quarter)

−$110.7M

Net income growth (year over year)

−30.73%

Net margin

—

Return on equity

−43.62%

EPS (trailing twelve months)

−$4.74

Book value per share

$12.84

P/E (trailing twelve months)

—

Price to book

2.68

Debt to assets

4.12%

Payout ratio

—

Dividend yield

—

Company profile

Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.

• How do I buy stock in Xenon Pharmaceuticals (XENE)?

  XENE trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.